FIG. 1A



15000
10000
5000
Intensity (counts)
5
10
15
20
25
30
35
θ-2θ (deg)
Image by PatternMatch v3.0.4

FIG. 1B




FIG. 1C




FIG. 1D



Taken at 25C/53%RH
Counts
2000
1000
0
10
20
30
40
Position [°2Theta] (Copper (Cu))

FIG. 2A



30%
25%
20%
15%
10%
5%
0%
% retained
7 kN, 1 mm screen
5 kN, 1 mm screen
3 kN, 1mm screen
3 kN, 1.25 mm screen
850
600
425
250
180
63
Fines
Sieve opening, um

FIG. 2B



4
3.5
3
2.5
2
1.5
1
0.5
0
Tensile Strength (MPa)
3 kN, 1mm screen
3 kN, 1.25 mm screen
5 kN, 1 mm screen
7 kN, 1 mm screen
0
50
100
150
200
250
300
Upper Punch Compression Pressure for 3/8" FFBE (Mpa)

FIG. 3



100
80
60
40
20
0
Compound I Released (%)
0
10
20
30
40
50
60
70
Time (min)
Fm (HPMC, poloxamer 188)
Fl (HPMC poloxamer 407)
Fk (poloxamer 407)
Fx

FIG. 4



Intensity (counts)
22500
16000
2500
0
Final blend
Milled granules
IG blend
Bis-MSA of Formula IA
5
10
15
20
25
30
35
2Theta (°)

FIG. 5



Intensity (counts)
Placebo Blend
Crushed Tablet
Final Blend
Spray-dried Material
0
100
400
800
5
10
15
20
25
30
35
2Theta (°)

FIG. 6



Intensity (counts)
1600
900
400
100
0
5
10
15
20
25
30
35
2Theta (°)
40°C, 75% RH, open 3 months
40°C, 75% RH, open 1 month
t=0

FIG. 7



Compound of
Formula I:
HPMC
Bis-MSA Salt of
Formula IA
40C/75% RH open 3 mos.
t_g = 12-3-12
Dried at 40C for 16 hrs
150
100
50
[ppm]

FIG. 8A



3 kN/cm force, 1.25 mm screen
3 kN/cm force, 1 mm screen
5 kN/cm force, 1 mm screen
% Retained
40
35
30
25
20
15
10
5
0
850
600
425
300
180
63
0
Sieve Size (um)

FIG. 8B



Compact Tensile Strength (MPa)
0
1
2
3
4
5
6
0
50
100
150
200
250
300
Upper Punch Pressure (MPa)
3 kN/cm force, 1.25 mm screen
3 kN/cm force, 1.25 mm screen
5 kN/cm force, 1 mm screen

FIG. 9



% Compound of Formula I dissolved in 50 mM sodium acetate, pH 4.5, containing 1% CTAB
% GS-9973 dissolved
0
1
2
3
4
5
6
7
8
9
0
10
20
30
40
50
60
Time (min)
F1
F6

FIG. 10



Intensity (counts)
1600
900
400
100
0
crushed tablet, 2 months
40°C/75% RH
crushed tablet, t=0
5
10
15
20
25
30
35
2Theta (°)

FIG. 11



Pentagastrin; mono-MSA salt of Formula IA
Famotidine; monohydrate, bis-MSA salt of Formula IA Form 3, spray dried
Famotidine; monohydrate, bis-MSA salt of Formula IA, Form 3, dry granulation tablet
Famotidine; mono-MSA salt of a compound of Formula I
2000
1500
1000
500
0
0
2
4
6
8
10
12

FIG. 12



Compound of Formula I AUC$_{tau}$ (h*ng/ml)
800000
700000
600000
500000
400000
300000
200000
100000
0
600 fasted
900 fasted
1200 fasted
Formulation 1 alone
Formulation 2 alone
median (Q1,Q3)

FIG. 13



Intensity (counts)
5000
4000
3000
2000
1000
0
4
6
8
10
12
14
16
18
20
22
24
26
28
2Theta (°)
2months, 75% RH
Initial (2.5 eq.)
2months, 75% RH
Initial (2.3 eq.)
2months, 75% RH
Initial (2.1 eq.)
2months, 75% RH
Initial (1.9 eq.)

FIG. 14A



C20
N6
C21
C22
N7
C19
C23
C18
C17
C16
C15
N4
C14
N3
C11
C12
C13
N5
N2
C9
C10
C8
C5
C7
C6
N1
C4
C3
C2
C1
O1
C24
O7B
S2
O5A
O6B
O6A
O7A
O5B
O1WA
O1WB
C25
O2
S1
O3
O4

FIG. 14B




FIG. 14C




FIG. 14D

